Chimeric antisense oligonucleotides and cell transfecting formulations thereof
AssigneeChiron Corporation
InventorsMIchael A. Innis, Christoph J. Reinhard, Ronald N. Zuckermann
Life of this patent
Estimating the term…
Loading patent…
AssigneeChiron Corporation
InventorsMIchael A. Innis, Christoph J. Reinhard, Ronald N. Zuckermann
Estimating the term…
Chimeric oligonucleotide of the formula 5′-W-X1-Y-X2-Z-3′, where W represents a 5′-O-alkyl nucleotide, each of X1 and X2 represents a block of seven to twelve phosphodiester-linked 2′-O-alkyl ribonucleotides, Y represents a block of five to twelve phosphorothioate-linked deoxyribonucleotides, and Z represents a blocking group effective to block nuclease activity at the 3′ end of the oligonucleotide, are described. These compounds exhibit high resistance to endo- and exonucleases, high sequence specificity, and the ability to activate RNAse H, as evidenced by efficient and long-lasting suppression of target mRNA. The oligonucleotides are preferably transfected into cells in formulations containing a lipid-peptoid conjugate carrier molecule of the formula L-linker-[N(CH2CH2NH2)CH2(C═O)-N(CH2CH2R)CH2(C═O)—N(CH2CH2R)CH2(C═O)]3-NH2, where L is a lipid moiety, including a steroid, and each group R is independently selected from alkyl, aminoalkyl, and aralkyl.
A chimeric oligonucleotide having the formula 5′-W-X1-Y-X2-Z-3′, where
Dependencies are inferred from the claim text.